Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells

Author(s): Cheng CY, Cherng SH, Wu WJ, Yang TY, Huang XY, et al.


Purpose: In terms of drug resistance, cancer cells usually benefit from high clusterin (CLU) expression on chemotherapy. In contrast, CLU expression has been found to be a favorable prognostic factor in lung cancer patients. The aims of this study are to determine the association between CLU expression and chemotherapeutic sensitivity and the potential role of CLU in migration in human non-small-cell lung cancer (NSCLC) cell lines.

Methods: The levels of clusterin in NSCLC cell lines were altered by short hairpin RNA interference (shRNAi) and overexpression on chemosensitivity assay. Migratory ability of these cell lines was also investigated.

Results: H1355 cells with the highest level of CLU demonstrated the lowest sensitivities to Adriamycin (ADR), docetaxel (DOC), and gemcitabine (GEM) treatment. Inhibition of CLU expression in H1355 cells resulted in higher chemosensitivities. When CLU was stably overexpressed in A549 and H1299 cells, only the chemosensitivity to ADR was reduced. The migratory ability of CLU-overexpressing cells significantly decreased. Moreover, MMP2 transcription was inhibited in CLU-overexpressing H1299 cells. These results indicated lower metastatic potential for cancer cells with high CLU level.

Conclusion: Lung cancer cells with high level of CLU have reduced chemosensitivity. High level of CLU may result in migratory inhibition and thus favorable prognosis in lung cancer.

Similar Articles

Current management of small cell lung cancer

Author(s): Neal JW, Gubens MA, Wakelee HA

Mechanisms of resistance to cisplatin

Author(s): Kartalou M, Essigmann JM

Expression of clusterin in human pancreatic cancer

Author(s): Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, et al.

Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer

Author(s): Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, et al.

Clusterin as a therapeutic target for radiation sensitization in a lung cancer model

Author(s): Cao C, Shinohara ET, Li H, Niermann KJ, Kim KW, et al.

Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway

Author(s): Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, et al.

Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin

Author(s): Guinea Viniegra J, Hernández Losa J, Sánchez-Arévalo VJ, ParadaCobo C, FernándezSoria VM, et al.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

Author(s): McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Author(s): McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al.

Raf kinase as a target for anticancer therapeutics

Author(s): Sridhar SS, Hedley D, Siu LL

Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair

Author(s): Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, et al.

Clusterin regulates drug-resistance in melanoma cells

Author(s): Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, et al.

The Raf/MEK/ERK pathway: new concepts of activation

Author(s): Peyssonnaux C, Eychène A